Related Experiment Video
Updated: Feb 3, 2026

Ex Vivo Organotypic Corneal Model of Acute Epithelial Herpes Simplex Virus Type I Infection
Published on: November 3, 2012
Primary infection with human herpes virus type 6, post-pediatric liver transplantation-A pathogen to remember
Adi Pappo-Toledano1, Sara Dovrat2, Zvia Soufiev2
1Department of Pediatrics C, Schneider Children's Medical Center, Petah Tiqva, Israel.
Insights
Primary Human herpes virus 6 (HHV-6) infection is a concern in young children after liver transplantation (LT). Early detection and antiviral treatment are crucial for preventing complications in pediatric liver transplant recipients.
Area of Science:
- Pediatric Hepatology
- Transplant Infectious Diseases
- Virology
Background:
- Liver transplantation (LT) is increasingly performed in children with end-stage liver disease at younger ages.
- Primary Human herpes virus 6 (HHV-6) infection is common in early childhood, but data in pediatric LT recipients is limited.
Purpose of the Study:
- To investigate the clinical presentation and outcomes of primary HHV-6 infection in pediatric liver transplant recipients.
Main Methods:
- Retrospective review of medical records (2015-2016) for pediatric patients post-LT with suspected primary HHV-6 infection.
- Evaluation of clinical, laboratory, and histopathological data.
- Definition of primary infection based on pre-transplant seronegativity or post-transplant seroconversion.
Main Results:
- Four cases of primary HHV-6 (type B) infection were identified in 26 pediatric LT recipients.
- All affected patients were under 1 year old and presented with fever, hepatitis, and elevated inflammatory markers, often shortly after LT.
- Three patients received antiviral therapy, leading to gradual symptom resolution; one case showed signs of liver transplant rejection.
Conclusions:
- Primary HHV-6 infection should be considered in young children post-LT presenting with fever and elevated liver enzymes.
- Prompt diagnosis and consideration of antiviral therapy can prevent serious complications in this vulnerable population.
Background:
In recent years, liver transplantation (LT) has become a well-accepted therapeutic modality for children with end-stage liver disease, with transplantation surgery being performed at a younger age. Human herpes virus 6 (HHV-6) infection occurs in most children within the first 2 years of life, therefore, data on primary HHV-6 infection in pediatric liver transplant recipients is scarce.
Objective:
To describe the course of primary HHV-6 infection after pediatric LT.
Methods:
Medical files, between the years 2015-2016, of post-LT pediatric patients with suspected primary HHV-6 infection were reviewed. Clinical and laboratory data for enrolled cases were evaluated. Primary infection was defined as DNAemia in children who were seronegative prior to transplantation or seroconversion from negative to positive IgG posttransplantation.
Results:
Four cases of primary HHV-6 (type B) infection were identified among the 26 children who had undergone LT at our center during the study period. All patients were <1 year old and presented with fever, hepatitis, and elevated inflammatory markers, most (75%) within a short-period posttransplantation. All were initially treated with empiric antibiotics for a suspected bacterial infection and three underwent liver biopsy, one showing signs of rejection. Three were treated with antiviral therapy with a gradual resolution of symptoms.
Discussion:
Primary HHV-6 should be taken into account in young children shortly after LT, especially when presenting with fever and elevated liver enzymes. Treatment with antiviral therapy should be considered.
Conclusions:
In young infants post-LT, a high index of suspicion may promote early detection of HHV-6 primary infection and prevent serious complications.
Related Concept Videos
What are Viruses?
Types of Genetic Transfer Between Organisms
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pharmacokinetics in Pediatric Patients: Drug Distribution
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Defenses Against Pathogens and Herbivores

